Linked Article The following letter by Tucker & Miners, together with the response from J.K. Aronson published in this issue (http://dx.doi.org/10.1111/j.1365-2125.2011.03910.x), should be read in association with previously-published letters by C. Page (Br J Clin Pharm, 70: 912–913; http://dx.doi.org/10.1111/j.1365-2125.2010.03769.x) and J.D. Fitzgerald (Br J Clin Pharm, 71: 471–472; http://dx.doi.org/10.1111/j.1365-2125.2010.03842.x). The correspondence in its entirety relates to A manifesto for clinical pharmacology from principles to practice (Aronson JK. Br J Clin Pharm, 70: 3–13; http://dx.doi.org/10.1111/j.1365-2125.2010.03699.x).
What's in a name?
Version of Record online: 11 APR 2011
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society
British Journal of Clinical Pharmacology
Special Issue: Drug allergy: themed section
Volume 71, Issue 5, pages 785–786, May 2011
How to Cite
Tucker, G. T. and Miners, J. O. (2011), What's in a name?. British Journal of Clinical Pharmacology, 71: 785–786. doi: 10.1111/j.1365-2125.2010.03817.x
- Issue online: 11 APR 2011
- Version of Record online: 11 APR 2011
- Accepted manuscript online: 13 OCT 2010 10:54PM EST
- RECEIVED , 27 August 2010; ACCEPTED , 31 August 2010; ACCEPTED ARTICLE , 13 October 2010